Scribe Therapeutics’ Post

#RNA plays a crucial role in biology and is a powerful tool in modern medicine. At Elixirgen Therapeutics, we are reimagining the power of RNA to develop various technologies for the treatment of #RareDiseases. Learn more here: https://bit.ly/3MZIFVK

InVitria, Inc. is attending #ASGCT24 in Baltimore! We will be located at Booth 131. Stop by to learn how our sustainable recombinant technology has been implemented by #celltherapy and #genetherapy developers to enhance biomanufacturing and final formulation! Connect with us through the event meeting portal to schedule a meeting. Team Members attending include: Andrew Hamann, PhD, Mark Stathos, Ph.D., Jake Hanks, Marcus Curl, Elliott Renft, Colin Odishoo, and Scott Deeter. Here's how InVitria's innovations contribute to success: Sustainability A steadfast focus on reducing the environmental impact and ensuring a sustainable and ethical supply of critical components for clinical applications. Safety and Quality Our commitment to animal-free components significantly reduces the risk of contaminants and ensures higher manufacturing consistency. Performance Enhanced cell growth, productivity, and product yield, facilitating faster and more efficient production cycles. We believe these solutions are pivotal to a future where cell and gene therapy achieve their promise for patients. They are not just a step towards more ethical and sustainable practices but also a leap towards more reliable and efficient therapeutic production. #SustainableSolutions #CellTherapies #GeneTherapies #AnimalFree #CharmCity

#SDDS2024 Ready for the Stanford Drug Discovery Symposium Day 2 with SPARK Finland and KAJO Neurotechnologies, looking forward to discuss drug development with human Parkinson’s disease cell model

HELLO EVERYONE! In our latest video on Bioinsights Academy, where we dive into the 2024 Nobel Prize in Physiology and Medicine, awarded to Victor Ambros and Gary Ruvkun for their groundbreaking discovery of microRNAs! 🏆🔬 MicroRNAs have revolutionized our understanding of gene regulation, and their discovery has had a profound impact on fields like cancer research, developmental biology, and more. In this video, I walk you through the fascinating journey of how Ambros and Ruvkun uncovered the role of these small yet powerful molecules. If you're curious about how microRNAs work, their biogenesis, and their role in human health and disease, check it out here: 👇 🎥 Thank you for watching, and don’t forget to like, comment, and share! Let’s continue learning and exploring the wonders of science together. 🌱🔍 #NobelPrize2024 #microRNA #GeneRegulation #Biotechnology #BioinsightsAcademy #ScienceEducation #VictorAmbros #GaryRuvkun #MolecularBiology #LifelongLearning #LinkedInLearning https://lnkd.in/d56cWSU9

Looking forward to #SLAS2024 where we will be showcasing our ioCRISPR-Ready Cells™️ products. Our poster presentations will include data from two products - the recently launched CRISPR-Ready ioGlutamatergic Neurons™️ and the next product in the range - CRISPR-Ready ioMicroglia™️. Find out more in the press release. 👇📰 https://hubs.ly/Q02j60Vz0 ioCRISPR-Ready Cells are iPSC-derived human cells containing a constitutively-expressed Cas9 nuclease. They arrive ready-to-use and with simple protocols, allowing high gene knockout efficiencies and functional experimental readouts in a physiological relevant cellular model in days, significantly reducing experimental timelines. #CRISPR #Research #DrugDevelopment #SynBio #BioEngineering

#PrecisionTherapies are rapidly advancing, targeting #DNA, RNA, proteins, and more to provide multiomic and curative treatments. Our research at ARK Investment Management LLC suggests that the value of companies focused on precision therapies could grow by 28% annually over the next seven years, increasing from around $820 billion in 2023 to approximately $4.5 trillion by 2030. In this video, Brett Winton (our Chief Futurist) explains why this decade will be a game-changer for healthcare and investment opportunities. Capital at Risk. #ARKInvest #ActiveETFs #Genomics #ThematicInvesting

Adenine base editors, such as ABE7.10, enable programmable C•G to T•A point mutations, but editing efficiencies can be low at challenging loci in primary human cells. 🧬 Discover how Beam Therapeutics leveraged DNA variant libraries of adenine base editors, synthesized by Ranomics, to evolve ABE7.10 into the ABE8s with superior editing performance 👉 https://lnkd.in/gAJCq7TJ #beamtherapeutics #crisprcas9 #geneediting #genetherapy #geneticengineering #dna

What makes Aqtual different?   Our efficient, single-analyte platform is the first of its kind to measure regulatory active chromatin. This approach enables us to identify an entirely new category of organ-specific DNA signatures. Evaluating protein regulation, epigenetics, and transcriptomics through a routine blood test offers new clinical applications in almost every major disease area. Learn more about our technology: https://lnkd.in/ef_Jyree #fAqtual #Aqtual #RA #ChronicConditions

📣 Just 2 weeks to go! genedrive will be exhibiting at POCTInnovators: The Power To Disrupt Clinical EXPO! The event will be held on Monday 16th September 2024 at 15 Hatfields Conference Centre, in London. Join us in #London to learn more about how our #phamacogenetic point-of-care tests are being used to guide treatment in time critical situations. By providing automated result of CYP2C19 genotypes to inform clinicians on an individual’s metaboliser status; and by reducing the risk of aminoglycoside induced hearing loss (AIHL) by detecting a variant in the MT-RNR1 gene (m.1555A>G). #GDR #POCT #pointofcare #diagnostics #medtech #lifesciences #medicaldevices #pointofcaretesting #healthcare #innovation #pharmacogenomics #pharmacogenetics 

Our CEO, Tuyen Ong, MD, MBA, was featured in the latest episode of the Biotech2050! Hear Tuyen dive into his career journey and share insights on the importance of cross-disciplinary expertise and resilience in transforming the future of #GeneticMedicine.